Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

Vail-Bon Jie Yang Wan capsules to the consumer level. The product has been found to be tainted with the drug ingredients, ...

Herbals LLC has issued a nationwide recall of all lots of Vail-Bon Jie Yang Wan  supplement capsules due to the presence of ...

The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK's new drug application (NDA) for Blenrep ...

All patients were younger than 10 years of age. The patients received either high-dose treatments (0.5–1.0 mg subconjunctival depot, dexamethasone 4 mg/mL, or methylprednisolone acetate 40mg/mL,, and ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

A low-volume local anesthetic with IV dexamethasone in a superior trunk block procedure can reduce the risk of diaphragmatic paresis.